Please assess the completion status of the following clinical trial:

Trial Title: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CD20+ B-cell lymphoma or B-CLL~* Refractory/relapsed CLL, FL, and DLBCL~* At least 1 measurable lesion (greater than \[\>\] 1.5 centimeters \[cm\] in its largest dimension) with the exception of CLL~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy \>6 months~Exclusion Criteria:~* Prior use of any investigational antibody therapy within 6 months of study start~* Prior use of any anti-cancer vaccine~* Prior administration of rituximab within 3 months of study start~* Prior administration of radioimmunotherapy 3 months prior to study entry~* Central nervous system lymphoma~* History of other malignancy~* Evidence of significant, uncontrolled concomitant disease~* Abnormal laboratory values~* Patients with progressive multifocalleukoencephalopathy (PML)~* Infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CLL: 1000 mg Obinutuzumab (Type: EXPERIMENTAL): Participants with chronic lymphocytic leukemia (CLL) will receive 1000 milligrams (mg) obinutuzumab as an intravenous (IV) infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. The first infusion on Cycle 1 Day 1 will be given over two days: Day 1 and Day 2. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
- DLBCL: 1000 mg Obinutuzumab (Type: EXPERIMENTAL): Participants with diffuse large B-cell lymphoma (DLBCL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
- FL: 1000 mg Obinutuzumab (Type: EXPERIMENTAL): Participants with follicular lymphoma (FL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).